896
Views
50
CrossRef citations to date
0
Altmetric
Inflammatory Bowel Diseases

The burden of inflammatory bowel disease on health care utilization and quality of life

, , , , &
Pages 51-57 | Received 02 Jan 2012, Accepted 04 Apr 2012, Published online: 14 May 2012

References

  • Langan RC, Gotsch PB, Krafczyk MA, Skillinge DD. Ulcerative colitis: diagnosis and treatment. Am Fam Physician 2007;76:1323–30.
  • Loftus EV, Sandborn WJ. Epidemiology of inflammatory bowel diseases. Gastroenterol Clin North Am 2002;31:1–20.
  • Manninen P, Karvonen A-L, Huhtala H, Rasmussen M, Collin P. The epidemiology of inflammatory Bowel diseases in Finland. Scand J Gastroenterol 2010;45:1063–7.
  • Statistical Yearbook of the Social Insurance Institution 2009. Vammala, Finland: Kela. 2010. Available from www.kela.fi/it/kelasto/kelasto.nsf/alias/Vk_09_pdf/$File/Vk_09_pdf? OpenElement. (Accessed 1.04.2012).
  • Gibson TB, Ng E, Ozminkowski RJ, Wang S, Burton WN, Goetzel RZ, The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med 2008;50:1261–72.
  • Bernklev T, Jahnsen J, Henriksen M, Lygren I, Aadland E, Sauar J, Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory Bowel disease. Inflamm Bowel Dis 2006;12:402–12.
  • Prenzler A, Bokemayer B, von der Schulenburg J-M, Mittendorf T. Health care costs and their predictors of inflammatory Bowel Diseases in Germany. Eur J Health Econ 2011;12:273–83.
  • Bernklev T, Jahnsen J, Aadland E, Sauar J, Schulz T, Lygren I, Health-related quality of life in patients with inflammatory Bowel disease five years after the initial diagnosis. Scand J Gastroenterol 2004;39:365–73.
  • Casellas F, López-Vivancos J, Badia X, Vilaseca J, Malagelada J-R. Influence of inflammatory Bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol 2001;13:567–72.
  • Longobardi T, Bernstein C. Health care resource utilization in inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:731–43.
  • Stark R, König HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics 2006;24:797–814.
  • Ebinger M, Leidl R, Thomas S, von Tirpitz C, Reinshagen M, Adler G, Cost of outpatient care in patients with inflammatory bowel disease in a German University hospital. J Gastroenterol Hepatol 2004;19:192–9.
  • Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004;53:1471–8.
  • Feagan B, Bala M, Yan S, Olson A, Hanauer S. Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol 2005;39:390–5.
  • Gibson P, Weston A, Shann A, Florin T, Lawrance I, Macrae F, Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn's disease. J Gastroenterol Hepatol 2007;22:1306–12.
  • Graff LA, Walker JR, Lix L, Clara I, Rawsthorne P, Rogala L, The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol 2006;4:1491–501.
  • Guassora AD, Kruuse C, Thomsen OO, Binder V. Quality of life study in a regional group of patients with Crohn disease. A structured interview study. Scand J Gastroenterol 2000;35:1068–74.
  • Han SW, McColl E, Barton JR, James P, Steen IN, Welfare MR. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm Bowel Dis 2005;11:24–34.
  • Hillilä MT, Färkkilä NJ, Färkkilä MA. Societal costs for irritable bowel syndrome – a population based study. Scand J Gastroenterol 2010;45:582–91.
  • Guyatt G, Mitchell A, Irvine E, Singer J, Williams N, Goodacre R, A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804–10.
  • Haapamäki J, Turunen U, Roine RP, Färkkilä MA, Arkkila PET. Impact of demographic factors, medication and symptoms on disease-specific quality of life in inflammatory bowel disease. Qual Life Res 2009;18:961–9.
  • Odes S, Vardi H, Friger M, Wolters F, Russel M, Riis L, Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006;131:719–28.
  • Feagan B, Panaccione R, Sandborn W, D'Haens GR, Schreiber S, Rutgeerts P, Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008;135:1493–9.
  • Cohen R, Yu A, Wu E, Xie J, Mulani P, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther 2010;31:693–707.
  • Ananthakrishnan A, Weber L, Knox J, Skaros S, Emmons J, Lundeen S, Permanent work disability in Crohn's disease. Am J Gastroenterol 2008;103:154–61.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.